Literature DB >> 21139091

Lifetime costs of medical care after heart failure diagnosis.

Shannon M Dunlay1, Nilay D Shah, Qian Shi, Bruce Morlan, Holly VanHouten, Kirsten Hall Long, Véronique L Roger.   

Abstract

BACKGROUND: Heart failure (HF) care constitutes an increasing economic burden on the health care system, and has become a key focus in the health care debate. However, there are limited data on the lifetime health care costs for individuals with HF after initial diagnosis. METHODS AND
RESULTS: Olmsted County residents with incident HF from 1987 to 2006 were identified. Direct medical costs incurred from the time of HF diagnosis until death or last follow-up were obtained using population-based administrative data through 2007. Costs were inflated to 2008 US dollars using the general Consumer Price Index. Inpatient, outpatient, and total costs were estimated using a 2-part model with adjustment for right censoring of data. Predictors of total costs were examined using a similar model. A total of 1054 incident HF patients were identified (mean age, 76.8 years; 46.1% men). After a mean follow-up of 4.6 years, 765 (72.6%) patients had died. The estimated total lifetime costs were $109 541 (95% confidence interval, $100 335 to 118 946) per person, with the majority accumulated during hospitalizations (mean, $83 980 per person). After adjustment for age, year of diagnosis, and comorbidity, diabetes mellitus and preserved ejection fraction (≥50%) were associated with 24.8% (P=0.003) and 23.6% (P=0.041) higher lifetime costs, respectively. Higher costs were observed at initial HF diagnosis and in the months immediately before death in those surviving >12 months after diagnosis.
CONCLUSIONS: HF imposes a significant economic burden, primarily related to hospitalizations. Variations in cost over a lifetime can help identify strategies for efficient management of patients, particularly at the end of life.

Entities:  

Mesh:

Year:  2010        PMID: 21139091      PMCID: PMC3057895          DOI: 10.1161/CIRCOUTCOMES.110.957225

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  23 in total

1.  Health economics of heart failure.

Authors:  M Malek
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

2.  Estimating log models: to transform or not to transform?

Authors:  W G Manning; J Mullahy
Journal:  J Health Econ       Date:  2001-07       Impact factor: 3.883

3.  Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder.

Authors:  C L Leibson; S K Katusic; W J Barbaresi; J Ransom; P C O'Brien
Journal:  JAMA       Date:  2001-01-03       Impact factor: 56.272

4.  The current cost of heart failure to the National Health Service in the UK.

Authors:  Simon Stewart; Andrew Jenkins; Scot Buchan; Alistair McGuire; Simon Capewell; John J J V McMurray
Journal:  Eur J Heart Fail       Date:  2002-06       Impact factor: 15.534

5.  History of the Rochester Epidemiology Project.

Authors:  L J Melton
Journal:  Mayo Clin Proc       Date:  1996-03       Impact factor: 7.616

6.  Costing medical care: using Medicare administrative data.

Authors:  J R Lave; C L Pashos; G F Anderson; D Brailer; T Bubolz; D Conrad; D A Freund; S H Fox; E Keeler; J Lipscomb
Journal:  Med Care       Date:  1994-07       Impact factor: 2.983

7.  Economic impact of heart failure in the United States: time for a different approach.

Authors:  J B O'Connell; M R Bristow
Journal:  J Heart Lung Transplant       Date:  1994 Jul-Aug       Impact factor: 10.247

8.  Why are patients in clinical trials of heart failure not like those we see in everyday practice?

Authors:  Ffion Lloyd-Williams; Frances Mair; Christopher Shiels; Barbara Hanratty; Pauline Goldstein; Susan Beaton; Simon Capewell; Michael Lye; Ruth Mcdonald; Christopher Roberts; Derek Connelly
Journal:  J Clin Epidemiol       Date:  2003-12       Impact factor: 6.437

9.  Trends in heart failure incidence and survival in a community-based population.

Authors:  Véronique L Roger; Susan A Weston; Margaret M Redfield; Jens P Hellermann-Homan; Jill Killian; Barbara P Yawn; Steven J Jacobsen
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

10.  Coronary disease surveillance in Olmsted County objectives and methodology.

Authors:  Véronique L Roger; Jill Killian; Mary Henkel; Susan A Weston; Tauqir Y Goraya; Barbara P Yawn; Thomas E Kottke; Robert L Frye; Steven J Jacobsen
Journal:  J Clin Epidemiol       Date:  2002-06       Impact factor: 6.437

View more
  93 in total

1.  Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure.

Authors:  Loretta Fala
Journal:  Am Health Drug Benefits       Date:  2015-09

Review 2.  Contemporary strategies in the diagnosis and management of heart failure.

Authors:  Shannon M Dunlay; Naveen L Pereira; Sudhir S Kushwaha
Journal:  Mayo Clin Proc       Date:  2014-03-29       Impact factor: 7.616

3.  Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.

Authors:  Yariv Gerber; Susan A Weston; Cecilia Berardi; Sheila M McNallan; Ruoxiang Jiang; Margaret M Redfield; Véronique L Roger
Journal:  Am J Epidemiol       Date:  2013-08-29       Impact factor: 4.897

4.  Care in the last year of life for community patients with heart failure.

Authors:  Shannon M Dunlay; Margaret M Redfield; Ruoxiang Jiang; Susan A Weston; Véronique L Roger
Journal:  Circ Heart Fail       Date:  2015-04-01       Impact factor: 8.790

5.  Hospice care and resource utilization in Medicare beneficiaries with heart failure.

Authors:  Saul Blecker; Gerard F Anderson; Robert Herbert; Nae-Yuh Wang; Frederick L Brancati
Journal:  Med Care       Date:  2011-11       Impact factor: 2.983

6.  Healthcare resource use among heart failure patients in a randomized pilot study of a cognitive training intervention.

Authors:  Susan J Pressler; Alison Martineau; Judith Grossi; Bruno Giordani; Todd M Koelling; David L Ronis; Penny L Riley; Cheng-Chen Chou; Barbara J Sullivan; Dean G Smith
Journal:  Heart Lung       Date:  2013-07-01       Impact factor: 2.210

7.  Contributors to frequent telehealth alerts including false alerts for patients with heart failure: a mixed methods exploration.

Authors:  K Radhakrishna; K Bowles; A Zettek-Sumner
Journal:  Appl Clin Inform       Date:  2013-10-09       Impact factor: 2.342

Review 8.  Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction.

Authors:  Matthias Barton; Oliver Baretella; Matthias R Meyer
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

9.  Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure.

Authors:  Loretta Fala
Journal:  Am Health Drug Benefits       Date:  2016-03

10.  Participation in cardiac rehabilitation, readmissions, and death after acute myocardial infarction.

Authors:  Shannon M Dunlay; Quinn R Pack; Randal J Thomas; Jill M Killian; Véronique L Roger
Journal:  Am J Med       Date:  2014-02-18       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.